ImmunOs Therapeutics will finance completion of Phase Ia of its ongoing clinical trial, thanks to €11 million of fresh capital. This was the amount raised in a Series C financing round, according to a press release issued by the company, which is based in Schlieren in the Swiss canton of Zurich and focuses on immuno-oncology.
The funding round was led by existing investors Gimv from Antwerp, Pfizer Ventures from New York, Mission BioCapital from San Francisco and BioMed Partners from Basel, with support from new investor Double Point Ventures from Palm Beach in Florida and other existing venture capital investors. ImmunOs Therapeutics has “large potential as a first-in-class immunotherapy approach for the treatment of both solid and liquid tumors,” says Campbell Murray, Advisor at Double Point Ventures.
According to the press release, the proceeds will be used to further fund the ongoing clinical trial of the IOS-1002 program, up to completion of clinical Phase Ia. IOS-1002 is a novel, multifunctional immunotherapy agent for the treatment of advanced solid tumors that simultaneously targets several immune checkpoints and is based on a naturally occurring human leukocyte antigen (HLA).
“IOS-1002 is the most advanced HLA-based program worldwide addressing these relevant targets and offering such a novel, multifunctional immunotherapy approach,” says Reinhard Ambros, Executive Chairman of the Board of ImmunOs Therapeutics. In conjunction with this round, Steve Tregay, Managing General Partner of Mission BioCapital, has joined the company’s Board of Directors.
ImmunOs Therapeutics AG is a spin-off of the University of Zurich and the University of Basel, and is based in the Bio-Technopark Schlieren-Zürich. ce/mm
Related news
Meet with an expansion expert
Our services are free of charge and include:
- Introduction to key contacts in industry, academia, and government
- Advice on regulatory framework, taxes, labor, market, and setting up a company
- Custom-made fact-finding visits, including office and co-working space